KDM3A Antibody

1. ormal stromal restricts cancer cell proliferation through JMJD1a-dependent modulation of gene expression. PMID: 27488962
2. JMJD1A was found to interact with and promote the recruitment of HNRNPF and thus splicing of AR-V7 resulting in prostate cancer. PMID: 29712835
3. High JMJD1A expression is associated with lymph node metastasis in oral and oropharyngeal squamous cell carcinoma. PMID: 29590186
4. In the present report, hypoxia is shown to activate a HIF-KDM3A-MMP12 signaling cascade that promotes trophoblast invasion and trophoblast-directed uterine spiral artery remodeling. PMID: 27807143
5. JMJD1A and c-Myc levels are independent prognostic factors for cervical cancer patients PMID: 27835890
6. Data suggest a critical role for KDM3A in the PI3K/AP-1 oncogenic axis and propose a novel strategy for inhibition of KDM3A against liver tumor development under PI3K pathway activation. PMID: 28692045
7. The authors find that KDM3A promotes anoikis through transcriptional activation of BNIP3 and BNIP3L, which encode pro-apoptotic proteins. PMID: 27472901
8. The KDM3A to PRM1 mRNA expression ratio can be used as a reliable marker of successful testicular sperm extraction in men with obstructive and non-obstructive azoospermia with 95% sensitivity. PMID: 27027467
9. Authors show that KDM3A regulates MCAM expression both through a direct mechanism, involving modulation of H3K9 methylation at the MCAM promoter, and an indirect mechanism, via the Ets1 transcription factor. PMID: 28319067
10. JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of HIF1alpha. PMID: 28263974
11. depletion of KDM3A was capable of reactivating mutated p53 to induce the expression of pro-apoptotic genes in breast cancer with mutant p53. KDM3A knockdown also potently inhibited tumorigenic potentials of breast cancer stem-like cells and rendered them sensitive to apoptosis induced by chemotherapeutic drugs. PMID: 27270439
12. our findings reveal a novel mechanism by which KDM3A promotes ovarian CSCs, proliferation and chemoresistance and thus, highlights the significance of KDM3A as a novel therapeutic target for resistant ovarian cancer. PMID: 27694900
13. a critical role for JMJD1A in regulating proliferation and survival of prostate cancer cells by controlling c-Myc expression at transcriptional and post-translational levels PMID: 26279298
14. deficient expression of JMJD1A/JMJD1A might be reflecting and/or contributing to round spermatid maturation arrest PMID: 27692601
15. JMJD1A could promote non-small cell lung cancer tumorigenesis PMID: 26945572
16. Study identified KDM3A an H3K9me2 demethylase, as responsible for the H3K9me2 reduction and critical for breast tumor transformation. PMID: 27034728
17. JMJD1A-MALAT1-MAPK signaling might participate in the JMJD1A-induced cell proliferation of gastric cancer. PMID: 26617828
18. These results indicate that the KDM3A-KLF2-IRF4 pathway plays an essential role in multiple myeloma cell survival and homing to the bone marrow, and therefore represents a therapeutic target. PMID: 26728187
19. JMJD1A is phosphorylated at S265 by protein kinase A (PKA), and this is pivotal to activate the beta1-adrenergic receptor gene (Adrb1) and downstream targets including Ucp1 in brown adipocytes. PMID: 25948511
20. Loss of JMJD1A expression is associated with liver fibrosis. PMID: 25609425
21. mitogen- and stress-activated protein kinase 1 (MSK1) specifically phosphorylates KDM3A at Ser264 (p-KDM3A), which is enriched in the regulatory regions of gene loci in the human genome. PMID: 25535969
22. Studies identify the histone demethylase KDM3A as a new, miR-regulated, tumor promoter in Ewing Sarcoma. PMID: 24362521
23. ACK1 interacts with KDM3A to regulate the mammary tumor oncogene HOXA1. PMID: 25148682
24. data identify a novel pathway through which N-Myc causes neuroblastoma cell migration and invasion, and provide important evidence for further development of more potent JMJD1A/MALAT1 inhibitors for the prevention of tumor metastasis. PMID: 24742640
25. Studies found that JMJD1A was consistently and significantly downregulated at both RNA and protein levels in human germ cell tumors. PMID: 25071150
26. JMJD1A forms a homodimer through its catalytic domains, bringing the two active sites close together PMID: 24214985
27. Expression of JHDM2A was significantly increased but HDAC2, HDAC7, and SUV39H2 were significantly down-regulated in Systemic Sclerosis B cells relative to controls PMID: 23891737
28. A single amino acid in KDM3A, T667, affects histone demethylase activity towards H3K9me1 and -me2. PMID: 23593242
29. Data indicate that JMJD1A gene silencing abrogated the hypoxia-induced adrenomedullin (ADM) expression and inhibited HepG2 and Hep3B cell growth. PMID: 23583388
30. Exposing cells to either chemical or cellular sources of (*)NO resulted in a significant increase in dimethyl Lys-9 on histone 3 (H3K9me2), the preferred substrate for KDM3A. PMID: 23546878
31. Our results suggest that LANA may play a role in regulation of epigenetic marks on the KSHV genome, which is in part through association with the histone demethylase KDM3A. PMID: 23576503
32. our results suggest that JMJD1A is a sensitive recurrence marker, and JMJD1A can promote malignant transformation via epithelial-mesenchymal transition. PMID: 21607773
33. KDM3A is recruited to the SLC2A3 locus in an HIF1-dependent manner and demethylates H3K9me2 so as to upregulate its expression. PMID: 22645302
34. Findings suggest that both Ni(2+) and ascorbate can regulate the expression of histone demethylase JMJD1A, which is important for cancer development or inhibition. PMID: 22318714
35. study demonstrates KDM3A is overexpressed in various types of cancer and directly activates transcription of HOXA1 through demethylation of histone H3K9 by binding to its promoter region PMID: 22020899
36. Up-regulation of miR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A, and results in downregulation of JMJD1A. PMID: 21541331
37. the increased expression of JMJD1A might be associated with the progression of kidney cancer. PMID: 21275466
38. Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer. PMID: 20823141
39. identification of genetic alterations & expression changes of LSD1, JHDM2A & GASC1 in prostate cancer (PC); as no genetic alterations & only modest expression changes were found, it is unlikely they play a major role in progression of PC PMID: 20127736
40. Data show that the JMJD1A/ABH2 family of dioxygenases is highly sensitive to inhibition by carcinogenic nickel ions. PMID: 20042601
41. Hypoxic regulation of JMJD1A acts as a signal amplifier to facilitate hypoxic gene expression, ultimately enhancing tumor growth. PMID: 19858293
42. These findings demonstrate that JMJD1A can be stimulated by hypoxia both in vitro and in vivo involving binding of HIF-1 to a specific HRE in the JMJD1A promoter. PMID: 18538129
43. Results show that many genes regulated by hypoxia and HIF-1alpha show patterns of induction with JMJD (Jumonji-domain containing)1A and JMJD2B demonstrating robust, and JMJD2C more modest, up-regulation by hypoxia. PMID: 18713068
44. histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF PMID: 18984585
45. Immunohistochemical staining has revealed that JMJD1A is widely expressed in tissues, even in cells that are not known to express the androgen receptor, and is significantly increased in smooth muscle cells upon hypoxia treatment. PMID: 19471969

Show More

Hide All

HGNC: 20815

OMIM: 611512

KEGG: hsa:55818

STRING: 9606.ENSP00000323659

UniGene: Hs.557425